Familial Adenomatous Polyposis Epidemiology Forecast Insight

DelveInsight’s ‘Familial Adenomatous Polyposis (FAP)–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Familial Adenomatous Polyposis (FAP), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Familial Adenomatous Polyposis (FAP) Disease Understanding

Familial adenomatous polyposis (FAP) is a rare inherited cancer predisposition syndrome characterized by hundreds to thousands of precancerous colorectal polyps (adenomatous polyps). If left untreated, affected individuals inevitably develop colon and/or rectum cancer at a relatively young age. In addition, an increased risk exists for the development of other malignancies.

 

FAP is caused by mutations in the adenomatous polyposis coli (APC) gene. The mutations interfere with the protein’s function made by the gene, allowing cells to grow uncontrolled and predispose them to become cancers. Most patients with FAP inherit a mutation in APC from one of their parents, who were also affected by the condition. About 25% of the time, the mutation occurs when a patient is conceived, and in this case, there is no family history of FAP in the parents.

 

Classic FAP is characterized by hundreds to thousands of colorectal adenomatous polyps, with polyps appearing in the teen years or early 20s. Without colectomy, affected individuals usually develop colorectal cancer by the third or fourth decade of life. FAP is also associated with an increased risk for cancer of the small intestine, including the duodenum, and cancer of the thyroid, pancreas, liver (hepatoblastoma), central nervous system (CNS), and bile ducts; however, these typically occur in less than 10% of affected individuals.

 

FAP is passed from generation to generation in a family. Genetic alterations in the APC gene present at birth are linked to FAP, AFAP, Gardner syndrome, and Turcot syndrome. This type of change to a gene can also be called a genetic mutation, gene alteration, pathogenic or likely pathogenic germline variant, or a disruptive gene change. A genetic alteration that disrupts the function of the APC gene gives a person an increased lifetime risk of developing multiple colorectal polyps (from tens to hundreds), as well as colorectal cancer and/or other cancers of the digestive tract.

 

Most patients with FAP are diagnosed through family screening as either of their parents has the condition. In the majority, genetic testing is generally done in teenagers. In those families where a causative mutation has not been identified, endoscopic surveillance should start at around this age. Screening for FAP at a younger age is not recommended for ethical reasons. As the intervention is rarely required before the mid-to-late teens, it is not considered appropriate to test children long before when necessary – when a delay would not affect their management and allow them to be involved in counseling and decision making.

 

Blood tests are available to look for disruptive changes in the APC gene and/or MUTYH gene if FAP or its subtypes are suspected. If an alteration is found in the APC gene, other family members may be diagnosed with FAP or its subtypes if tested and have the same gene mutation.

The mainstay of this condition’s management is the surgical removal of the large bowel as, except in very rare cases of attenuated FAP, it is still not possible to manage a large number of adenomas endoscopically.

 

Desmoid tumors are benign but may cause problems by compressing organs and/or blood vessels in the abdomen. These are treated variously with surgery, NSAIDs, anti-estrogen medications, chemotherapy and/or radiation, depending on the details in each case.

Familial Adenomatous Polyposis (FAP) Epidemiology

The Familial Adenomatous Polyposis (FAP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Familial Adenomatous Polyposis (FAP) epidemiology segmented as the Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis. The report includes the Incident scenario of Familial Adenomatous Polyposis (FAP) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Familial Adenomatous Polyposis (FAP) Epidemiology

The epidemiology segment also provides the Familial Adenomatous Polyposis (FAP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total population of Familial Adenomatous Polyposis (FAP) Associated in 7MM countries was estimated to be 60.,661 cases in 2020 and expected to increase at a CAGR of 0.52% for the study period, i.e., 2018–2030.
  • As per the estimates, United States has the highest incident population of Familial Adenomatous Polyposis (FAP) in 7MM.
  • Among the EU5 and 7MM countries, Germany had the highest incident population of Familial Adenomatous Polyposis (FAP). On the other hand, Spain had the lowest number of cases, 1,725 cases in 2020.

Scope of the Report

  • Familial Adenomatous Polyposis (FAP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Familial Adenomatous Polyposis (FAP) Epidemiology Report and Model provide an overview of the risk factors and global trends of Familial Adenomatous Polyposis (FAP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Familial Adenomatous Polyposis (FAP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Familial Adenomatous Polyposis (FAP)
  • The report provides the segmentation of the Familial Adenomatous Polyposis (FAP) epidemiology by incident Cases of Familial Adenomatous Polyposis (FAP) in 7MM
  • The report provides the segmentation of the Familial Adenomatous Polyposis (FAP) epidemiology by incidence of Familial Adenomatous Polyposis (FAP), Prevalent Cases of Familial Adenomatous Polyposis, Diagnosed cases of Familial Adenomatous Polyposis, Etiology-specific Prevalence of Familial Adenomatous Polyposis, Type-specific Prevalence of Familial Adenomatous Polyposis in 7MM

Report Highlights

  • 10-year Forecast of Familial Adenomatous Polyposis (FAP) epidemiology
  • 7MM Coverage
  • Prevalent Cases of Familial Adenomatous Polyposis
  • Diagnosed cases of Familial Adenomatous Polyposis
  • Etiology-specific Prevalence of Familial Adenomatous Polyposis
  • Type-specific Prevalence of Familial Adenomatous Polyposis

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Familial Adenomatous Polyposis (FAP)?
  • What are the key findings of Familial Adenomatous Polyposis (FAP) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2030)?
  • What would be the total number of patients with Familial Adenomatous Polyposis (FAP) across the 7MM during the forecast period (2021–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2030)?
  • What are the disease risk, burden, and unmet needs of Familial Adenomatous Polyposis (FAP)?
  • What are the currently available treatments for Familial Adenomatous Polyposis (FAP)?

Reasons to buy

The Familial Adenomatous Polyposis (FAP) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Familial Adenomatous Polyposis (FAP) market
  • Quantify patient populations in the global Familial Adenomatous Polyposis (FAP) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Familial Adenomatous Polyposis (FAP) therapeutics in each of the markets covered
  • Understand the magnitude of Familial Adenomatous Polyposis (FAP) population by its incident cases
  • Understand the magnitude of Familial Adenomatous Polyposis (FAP) population by its risk factors cases
  • The Familial Adenomatous Polyposis (FAP) epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Familial Adenomatous Polyposis (FAP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Familial Adenomatous Polyposis Market Overview at a Glance

3.1. Market Share (%) Distribution of Familial Adenomatous Polyposis in 2018

3.2. Market Share (%) Distribution of Familial Adenomatous Polyposis in 2030

4. Executive Summary of Familial Adenomatous Polyposis

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Clinical Manifestations

5.4. Subtypes of FAP

5.5. Pathophysiology

5.6. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Familial Adenomatous Polyposis

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Familial Adenomatous Polyposis in the United States

6.4.2. Prevalent cases of FAP based on mutation in the United States

6.4.3. Type-specific Prevalence of Familial Adenomatous Polyposis in the United States

6.5. EU5

6.6. Germany

6.6.1. Prevalent Cases of Familial Adenomatous Polyposis in Germany

6.6.2. Prevalent cases of FAP based on mutation in Germany

6.6.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Germany

6.7. France

6.7.1. Prevalent Cases of Familial Adenomatous Polyposis in France

6.7.2. Prevalent cases of FAP based on mutation in France

6.7.3. Type-specific Prevalence of Familial Adenomatous Polyposis in France

6.8. Italy

6.8.1. Prevalent Cases of Familial Adenomatous Polyposis in Italy

6.8.2. Prevalent cases of FAP based on mutation in Italy

6.8.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Italy

6.9. Spain

6.9.1. Prevalent Cases of Familial Adenomatous Polyposis in Spain

6.9.2. Prevalent cases of FAP based on mutation in Spain

6.9.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Spain

6.10. United Kingdom

6.10.1. Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom

6.10.2. Prevalent cases of FAP based on mutation in the United Kingdom

6.10.3. Type-specific Prevalence of Familial Adenomatous Polyposis in the United Kingdom

6.11. Japan

6.11.1. Prevalent Cases of Familial Adenomatous Polyposis in Japan

6.11.2. Prevalent cases of FAP based on mutation in Japan

6.11.3. Type-specific Prevalence of Familial Adenomatous Polyposis in Japan

7. Treatment and Management

7.1. Guidelines

7.1.1. American Society for Gastrointestinal Endoscopy Guidelines

7.1.2. European Society of Gastrointestinal Endoscopy (ESGE) guideline

8. Patient Journey

9. Case Report

10. Organizations contributing towards Familial Adenomatous Polyposis (FAP)

11. Appendix

12. Bibliography

13. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Table

Table 1: Summary of Familial Adenomatous Polyposis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Diagnosed Prevalent Patient Population of Familial Adenomatous Polyposis in 7MM (2018–2030)

Table 3: Prevalent Cases of Familial Adenomatous Polyposis in the United States (2018–2030)

Table 4: Prevalent cases of FAP based on mutation in the United States (2018–2030)

Table 5: Type-specific Prevalence of Familial Adenomatous Polyposis in the United States (2018–2030)

Table 6: Prevalent Cases of Familial Adenomatous Polyposis in Germany (2018–2030)

Table 7: Prevalent cases of FAP based on mutation in Germany (2018–2030)

Table 8: Type-specific Prevalence of Familial Adenomatous Polyposis in Germany (2018–2030)

Table 9: Prevalent Cases of Familial Adenomatous Polyposis in France (2018–2030)

Table 10: Prevalent cases of FAP based on mutation in France (2018–2030)

Table 11: Type-specific Prevalence of Familial Adenomatous Polyposis in France (2018–2030)

Table 12: Prevalent Cases of Familial Adenomatous Polyposis in Italy (2018–2030)

Table 13: Etiology-specific Prevalence of Familial Adenomatous Polyposis in Italy (2018–2030)

Table 14: Type-specific Prevalence of Familial Adenomatous Polyposis in Italy (2018–2030)

Table 15: Prevalent Cases of Familial Adenomatous Polyposis in Spain (2018–2030)

Table 16: Prevalent cases of FAP based on mutation in Spain (2018–2030)

Table 17: Type-specific Prevalence of Familial Adenomatous Polyposis in Spain (2018–2030)

Table 18: Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom (2018–2030)

Table 19: Prevalent cases of FAP based on mutation in the United Kingdom (2018–2030)

Table 20: Type-specific Prevalence of Familial Adenomatous Polyposis in United Kingdom (2018–2030)

Table 21: Prevalent Cases of Familial Adenomatous Polyposis in Japan (2018–2030)

Table 22: Prevalent cases of FAP based on mutation in Japan (2018–2030)

Table 23: Type-specific Prevalence of Familial Adenomatous Polyposis in Japan (2018–2030)

Table 24: Organizations contributing towards Familial Adenomatous Polyposis

List of Figures

Figure 1: Endoscopic appearance of early FAP adenomas.

Figure 2: Illustrations of the extracolonic upper gastrointestinal polyp manifestations of FAP

Figure 3: Illustration of the extraintestinal manifestations of FAP

Figure 4: Prevalent Patient Population of Familial Adenomatous Polyposis in 7MM (2018–2030)

Figure 5: Prevalent Cases of Familial Adenomatous Polyposis in the United States (2018–2030)

Figure 6: Prevalent cases of FAP based on mutation in the US (2018–2030)

Figure 7: Type-specific Prevalence of Familial Adenomatous Polyposis in the United States (2018–2030)

Figure 8: Prevalent Cases of Familial Adenomatous Polyposis in Germany (2018–2030)

Figure 9: Prevalent cases of FAP based on mutation in Germany (2018–2030)

Figure 10: Type-specific Prevalence of Familial Adenomatous Polyposis in Germany (2018–2030)

Figure 11: Prevalent Cases of Familial Adenomatous Polyposis in France (2018–2030)

Figure 12: Prevalent cases of FAP based on mutation in France (2018–2030)

Figure 13: Type-specific Prevalence of Familial Adenomatous Polyposis in France (2018–2030)

Figure 14: Prevalent Cases of Familial Adenomatous Polyposis in Italy (2018–2030)

Figure 15: Prevalent cases of FAP based on mutation in Italy (2018–2030)

Figure 16: Type-specific Prevalence of Familial Adenomatous Polyposis in Italy (2018–2030)

Figure 17: Prevalent Cases of Familial Adenomatous Polyposis in Spain (2018–2030)

Figure 18: Prevalent cases of FAP based on mutation in Spain (2018–2030)

Figure 19: Type-specific Prevalence of Familial Adenomatous Polyposis in Spain (2018–2030)

Figure 20: Prevalent Cases of Familial Adenomatous Polyposis in the United Kingdom (2018–2030)

Figure 21: Prevalent cases of FAP based on mutation in the United Kingdom (2018–2030)

Figure 22: Type-specific Prevalence of Familial Adenomatous Polyposis in the United Kingdom (2018–2030)

Figure 23: Prevalent Cases of Familial Adenomatous Polyposis in Japan (2018–2030)

Figure 24: Prevalent cases of FAP based on mutation in Japan (2018–2030)

Figure 25: Type-specific Prevalence of Familial Adenomatous Polyposis in Japan (2018–2030)

Forward to Friend

Need A Quote